Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
May 13 2024 - 1:00AM
Press Release: Sanofi adds over €1 billion for
biomanufacturing to €2.5 billion already committed in
major projects in France to support health sovereignty
Sanofi adds over €1 billion for
biomanufacturing to €2.5 billion already committed in
major projects in France to support health sovereignty
Paris, May 13, 2024. As the
largest private contributor to the security and independence of
France's health ecosystem, Sanofi today announces an
investment of more than €1 billion to create new bioproduction
capacity at its sites in Vitry-sur-Seine (Val de Marne),
Le Trait (Seine-Maritime) and Lyon Gerland (Rhône). This new
investment will create more than 500 jobs and significantly
strengthen France's ability to control the production of essential
medicines from start to finish, for the present day and into the
future. This plan brings to more than €3.5 billion the
amount committed by Sanofi since the Covid-19 pandemic in major
projects to keep production of medicines and vaccines
in France for patients around the world.
- In
Vitry-sur-Seine, Sanofi will invest €1
billion to build a new facility that will double the
site's monoclonal antibody production capacity. Several biologics
in development amongst Sanofi’s 12 potential blockbusters, in
chronic obstructive pulmonary disorder (COPD), asthma, multiple
sclerosis or type 1 diabetes, could be produced in Vitry to meet
the needs of millions of patients in France and around the world.
Sanofi anticipates the creation of 350 jobs as a
result of this investment.
- At the Le Trait
site in Normandy, Sanofi will invest €100
million to develop new capacity for biologics formulation,
filling, device assembly and packaging. It will support the launch
of future biologics and vaccines, as well as the continued growth
of Dupixent®, which already is indicated in several inflammatory
diseases and could soon become the first biologic indicated in
COPD. This investment will support 150 jobs.
- In Lyon Gerland,
Sanofi is investing €10 million to locate the
production of TZield® in France. Tzield® is a biologic for type 1
diabetes that Sanofi acquired in April 2023 and which has been
manufactured outside Europe.
Paul HudsonChief Executive
Officer, Sanofi"Thanks to the transformation undertaken since 2020,
Sanofi has a record number of medicines and vaccines in development
that could become best-in-class and help meet major public health
challenges. With these unprecedented industrial investments, we
remain true to our history by once again choosing France to produce
these future medicines and make them available to patients around
the world. France is, and always will be, at the heart of Sanofi's
strategy."
Sanofi carries out more than 60% of its
global production in the European Union and sources only
5% of its active ingredients in Asia, compared to an average of 80%
in the pharmaceutical industry. Thanks to this industrial
footprint, Sanofi's contribution to France's trade balance
amounted to more than €13 billion in 2023.
These investments at Vitry, Le Trait and Lyon
Gerland add up to major projects launched since the Covid-19
pandemic to build in France new drugs and vaccines production
capacity in-line with Sanofi's world class pipeline of best
and first-in-class assets and meet public health needs. These
projects includes:
- In Neuville-sur-Saône,
nearly €500 million to build the world's first evolutive
facility for biological drugs and vaccines, including mRNA. It will
be low-carbon and meet LEED certification standards when it
launches in 2025.
- In Val de Reuil, €250
million to build Europe's largest flu vaccine production
unit and locate several production stages of Fluzone® High Dose /
Efluelda®, its high-dose flu vaccine, in France.
- In Sisteron, €60
million to build a small-volume launch unit for the
production of active ingredients.
- In Lisieux, €20
million to increase Doliprane®'s production capacity by
140 million boxes per year.
- In Tours, €15
million to locate the production of a drug to fight high
cholesterol in France. This investment will allow the construction
of a new high-volume granulation unit and a tablet-coating line in
a new building. The capacity of this new unit will be around 700
million boxes per year for some 20 countries, particularly in
Europe and Asia.
Audrey DerveloyPresident of
Sanofi France"Throughout its history, Sanofi has always sought to
equip France with the strategic platforms needed to produce the
essential medicines and vaccines of today and tomorrow. This is why
we chose our Vitry site to double its monoclonal antibody
production capacity, after having already invested heavily in
Neuville-sur-Saône to produce our future vaccines, including with
mRNA technology. We have also strengthened our API production sites
in the south of France. Our contribution to health sovereignty in
Europe, and France in particular, has always been and remains
unique."
These efforts are part of the new chapter of
Sanofi's Play to Win strategy presented at the end of 2023, which
focuses on cutting-edge science and its ambition to become the
world leader in immunology, targeting diseases such as asthma,
multiple sclerosis, type 1 diabetes and COPD. To support this
ambition, Sanofi will invest an additional €700 million per year in
R&D over the next two years. In 2023, Sanofi invested €6.7
billion in R&D.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across the world, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions. Sanofi is
listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on our employees and on
the global economy as a whole. The risks and uncertainties also
include the uncertainties discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F
for the year ended December 31, 2023. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Sanofi (EU:SAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Jul 2023 to Jul 2024